Herpesvirus and Enteric Viral Infections in Bone Marrow Transplantation Clinical Presentations, Pathogenesis, and Therapeutic Strategies

References

• Ho M. Human cytomegalovirus infections in immunocompromised patients. Cytomegalavirus: Biology and Infection, W B Greenough, III, T C Merigan. Plenum, New York 1982; 171–204
   Google Scholar
• Pollard I RB, Rand K H, Aroin A M, et al. Cell mediated immunity to cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis 1978; 137: 541–549
   PubMed Web of Science ®Google Scholar
• Elfenbein G J, Saral R. Infectious disease during immune recovery after bone marrow transplantation. Infection and the Compromised Host, J C Allen. Williams & Wilkins, Baltimore 1981; 157–196
   Google Scholar
• Vilmer E, Mazeron M C, Rabian C, et al. Clinical significance of cytomegalovirus viremia in bone marrow transplantation. Transplantation 1985; 40: 30–35
   PubMed Web of Science ®Google Scholar
• Guyotat D, Gibert R, Chomel J, et al. Incidence and prognosis of cytomegalovirus infections following allogenic bone marrow transplantation. J Med Virol 1987; 23: 393–399
   PubMed Web of Science ®Google Scholar
• Wasserman R, August C S, Platokin S A. Viral infections in pediatric bone marrow transplant patients. Pediatr Infect Dis J 1988; 7: 109–115
   PubMed Web of Science ®Google Scholar
• Wingard J, Piantadosi R. S, Burns W H, et al. Cytomegalovirus infections in patients treated by intensive cytoreductive therapy with marrow transplant. Rev Infect Dis 1989
   Google Scholar
• Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986; 67: 1162–1167
   PubMed Web of Science ®Google Scholar
• Meyers J E, Fluornoy N, Thomas E D. Risk factors for cytomegalovirus infection after human marrow transplantation. I Infect Dis 1986; 153: 478–488
   PubMed Web of Science ®Google Scholar
• Hersman J, Meyers J D, Thomas E D, et al. The effect of granulocyte transfusion upon the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med 1982; 96: 149–152
   PubMed Web of Science ®Google Scholar
• Paulin T, Ringden O, Lonnqvist B, et al. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. Scand J Infect Dis 1986; 18: 199–209
   PubMed Web of Science ®Google Scholar
• Winston D J, Huang E S, Miller M J, et al. Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. Ann Intern Med 1985; 102: 16–20
   PubMed Web of Science ®Google Scholar
• Shorr R I, Longo W L, Oberley T D, et al. Cytomegalovirus-associated tubulointerstitial nephritis in an allogeneic bone marrow transplant recipient. Ann Intern Med 1987; 107: 351–352
   PubMed Web of Science ®Google Scholar
• Bhawan J, Gellis S, Ucci A, Chang T W. Vesiculobullous lesions caused by cytomegalovirus infection in an immunocompromised adult. J Am Acad Dermatol 1984; 11: 743–747
   PubMed Web of Science ®Google Scholar
• Wingard J R, Sostrin M G, Vriesendorp H M, et al. Interstitial pneumonias following autologous bone marrow transplantation. Transplantation 1988; 46: 61–65
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Escudier E, Nicolas J C, et al. Evaluation of three assays on alveolar lavage fluid in the diagnosis of cytomegalovirus pneumonitis after bone marrow transplantation. J Infect Dis 1987; 155: 495–500
   PubMed Web of Science ®Google Scholar
• Wingard J R, Chen Y H, Burnw W H, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71: 1432–1437
   PubMed Web of Science ®Google Scholar
• Meyer J D, Flournoy N, Thomas E D. Nonbacterial pneumonia after allogeneic bone marrow transplantation: a review of ten years experience. Rev Infect Dis 1982; 4: 1119–1132
   PubMedGoogle Scholar
• Funada H, Harada M, Yoshida T, et al. Interstitial pneumonia after allogeneic and autologous bone marrow transplantation. Jpn J Clin Oncol 1984; 14: 519–530
   PubMed Web of Science ®Google Scholar
• Beschorner W E, Hutchins G M, Burns W H, et al. Cytomegalovirus pneumonia in bone marrow transplant recipients: miliary and diffuse patterns. Am Rev Resp Dis 1980; 122: 107–114
   PubMed Web of Science ®Google Scholar
• Lonnqvist B, Ringden O, Wahren B, et al. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation 1984; 38: 465–468
   PubMed Web of Science ®Google Scholar
• Miller W, Flynn P, McCullough, Jr, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986; 67: 1162–1167
   PubMed Web of Science ®Google Scholar
• Zaia J A. The biology of human cytomegalovirus infection after bone marrow transplantation. Int J of Cell Cloning 1986; 4: 135–154
   PubMedGoogle Scholar
• Zaia J A, Kovacs A, Forman S J. Human cytomegalovirus-associated pneumonitis: pathogenesis, prevention, and treatment. Transplant Proc 1987; 19: 125–131
   PubMed Web of Science ®Google Scholar
• Grundy J E, Shanley J D, Griffiths P D. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition?. Lancet 1987; 2: 996–999
   PubMed Web of Science ®Google Scholar
• Quinnan G V, Jr, Kirmani N, Rook A H, et al. Cytotoxic T cells in cytomegalovirus infection. HLA-restricted T lymphocyte and non-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med 1987; 307: 7–13
   Google Scholar
• Donnenberg A D, Hess A D, Duff S C, et al. Regeneration of genetically restricted immune functions after human bone marrow transplantation: influence of four different strategies for graft-v-host disease prophylaxis. Trans Proc 1987; 19: 144–152
   PubMed Web of Science ®Google Scholar
• Verdonck L F, van Heugten H, deGast G C. Delay in platelet recovery after bone marrow transplantation: impact of cytomegalovirus infection. Blood 1983; 66: 921–925
   Web of Science ®Google Scholar
• Paulin T, Ringden O, Loonqvist B. Faster immunological recovery after bone marrow transplantation in patients without cytomegalovirus infection. Transplantation 1987; 39: 377–384
   Web of Science ®Google Scholar
• Meyers J D, Flournoy N, Wade J C, . Biology of interstitial pneumonia after marrow transplantation. Recent Advances in Bone Marrow Transplantation, R P Gale, et al. Alan R. Liss, New York 1983; 405–423
   Google Scholar
• Meyers J D, McGuffin R W, Thomas E D. Prophylactic human leukocyte interferon after allogeneic marrow transplant: immunologic and virologic effects. Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, Florida, 190
   Google Scholar
• Kraemer K G, Neiman P E, Reeves C, et al. Prophylactic adenine arabinoside following marrow transplantation. Transplant Proc 1978; 10: 237–240
   PubMed Web of Science ®Google Scholar
• Wade J C, Hintz M, McGuffin R W, et al. Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med Acyclovir Symp 1982; 73: 249–256
   PubMed Web of Science ®Google Scholar
• Ashraf M H, Campalani G C, Qureshi S A, et al. Acyclovir in the treatment of cytomegalovirus pneumonia after cardiac transplantation. Lancet 1982; 1: 173–175
   PubMed Web of Science ®Google Scholar
• Eriksson B, Oberg B, Wahren B. Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus of cellular origin. Acta Biochim Acad Sci Hungar 1982; 696: 115–123
   Google Scholar
• Klintmalm G, Lonnqvist B, Oberg B, et al. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis. 1985; 17: 157–163
   PubMed Web of Science ®Google Scholar
• Ringden O, Lonnqvist B, Paulin T, et al. Pharmacokinetics, safety and preliminary clnical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother 1986; 17: 373–378
   PubMed Web of Science ®Google Scholar
• Mar E C, Cheng Y C, Huang E S. Effect of 9-(dihydroxy-2-propoxymethyl) guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1983; 24: 518–521
   PubMed Web of Science ®Google Scholar
• Keay R, Bissett J, Merigan T C. Ganciclovir treatment of cytomegalovirus infections in iatrogenically immunocompromised patients. J Infect Dis 1987; 156: 1016–1021
   PubMed Web of Science ®Google Scholar
• Selby P, Powles R L, Jameson B, et al. Treatment of cytomegalovirus pneumonitis after bone marrow transplantation with 9-[2-hydroxy-1(hydroxymethyl) ethoxymethyl] guanine [letter]. Lancet 1986; 1(8494)1377–1378
   PubMed Web of Science ®Google Scholar
• Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl) guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986; 314: 801–805
   PubMed Web of Science ®Google Scholar
• Erice A, Chou S, Biron K K, et al. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320: 289–293
   PubMed Web of Science ®Google Scholar
• Wilson E J, Medearis D N, Jr, Hansen L A, et al. 9-(1,3-Dihydroxy-2-propoxymethyl) guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob Agents Chemother 1987; 31: 1017–1020
   PubMed Web of Science ®Google Scholar
• Reed E C, Bowden R A, Dandliker P SA, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783–788
   PubMed Web of Science ®Google Scholar
• Bratanow N C, Ash R C, Turner P A, et al. Successful treatment of serious cytomegalovirus disease with 9(1,3-dihydroxy-2-propoxymethyl) guanine in bone marrow transplant (BMT) patients. Blood 1986; 68: 280a
   Google Scholar
• Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777–782
   PubMed Web of Science ®Google Scholar
• Bowden R A, Sayers M, Gleaves C A, et al. Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation. Considerations for blood banks. Transfusion 1987; 27: 478–481
   PubMed Web of Science ®Google Scholar
• Winston D J, Pollard R B, Ho W G, et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med 1982; 97: 11–18
   PubMed Web of Science ®Google Scholar
• Meyers J D, Leszczynstki J, Zaiz J A, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 1983; 98: 442–446
   PubMed Web of Science ®Google Scholar
• O'Reilly R J, Reich L, Gold J, et al. A randomized trial of intravenous hyper-immune globulin for the prevention of cytomegalovirus infections following marrow transplantation: preliminary results. Transpl Proc 1983; 15: 1405–1411
   Web of Science ®Google Scholar
• Bowden R A, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006–1110
   PubMed Web of Science ®Google Scholar
• Meyers J D, Leszczynski J, Zaia J A, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 1983; 98: 442–446
   PubMed Web of Science ®Google Scholar
• Meyers J D, Reed E C, Shepp D H, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70–75
   PubMed Web of Science ®Google Scholar
• Borysiewicz L K, Morris S, Page J D, et al. Human cytomegalovirus-specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity. Eur J Immun 1983; 13: 804–809
   PubMed Web of Science ®Google Scholar
• Meyers J D, Flournoy N, Thomas E D. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980; 142: 338–346
   PubMed Web of Science ®Google Scholar
• Hann I M, Prentice H G, Blacklock H A, et al. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomized double-blind trial. Br Med J 1983; 287: 348–388
   Google Scholar
• Saral R, Burns W H, Laskin O L, et al. Acyclovir prophylaxis of herpes-simplex-virus infections: a randomized, double-blind, controlled trial in bone-marrow-transplant recipients. N Engl J Med 1981; 305: 63–67
   PubMed Web of Science ®Google Scholar
• Meyers J D. Treatment of herpesvirus infections in the immunocompromised host. Scand J Infect Dis 1985; 47: 128–136
   Google Scholar
• Whitley R J, Levin M, Barton N, et al. Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy. J Infect Dis 1984; 150: 323–329
   PubMed Web of Science ®Google Scholar
• Whitley R J, Soong S J, Dolin R, et al. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. N Engl J Med 1977; 297: 289–294
   PubMed Web of Science ®Google Scholar
• Whitley R J, Nahmias Soong A J, et al. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 1980; 66: 495–501
   PubMed Web of Science ®Google Scholar
• Whitley R J, Spruance S, Hayden F G, et al. Vidarabine therapy for mucocutaneous herpes simplex virus infections in the immunocompromised host. J Infect Dis 1984; 149: 1–8
   PubMed Web of Science ®Google Scholar
• Bryson Y J, Maryanne D, Lovett M, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir: a randomized double-blind controlled trial in normal subjects. N Engl J Med 1983; 308: 916–921
   PubMed Web of Science ®Google Scholar
• Strauss S E, Smith H A, Brickman C, et al. Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients. Ann Intern Med 1982; 96: 270–277
   PubMed Web of Science ®Google Scholar
• Wade J C, Newton B, McLaren C, et al. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation. Ann Intern Med 1982; 96: 265–269
   PubMed Web of Science ®Google Scholar
• Shepp D H, Newton B A, Dandliker P S, et al. Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Ann Intern Med 1985; 102: 783–785
   PubMed Web of Science ®Google Scholar
• Burns W H, Saral R, Santos G W, et al. Isolation and characterization of resistant herpes simplex virus after acyclovir therapy. Lancet 1982; 1: 421–423
   PubMed Web of Science ®Google Scholar
• Burns W H, Saral R. Chemotherapy of herpes simplex virus infections. Human Immunity to Viruses, F A Ennis. Academic Press, New York 1983; 203–218
   Google Scholar
• Christophers J, Sutton R N, Noble R V, et al. Clinical resistance to acyclovir of herpes simplex virus infections in immunocompromised patients. J Antimicrob Chemother 1986; 18: 121–125
   PubMed Web of Science ®Google Scholar
• Wade J C, McLaren C, Meyers J D. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis 1983; 148: 1077–1082
   PubMed Web of Science ®Google Scholar
• Erlich K S, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 293–297
   PubMed Web of Science ®Google Scholar
• Chatis P A, Miller C H, Schrager L E, Crumpacker C S. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 297–300
   PubMed Web of Science ®Google Scholar
• Field J H, Darbe G. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob Agents Chemother 1980; 17: 209–216
   PubMed Web of Science ®Google Scholar
• Ambinder R F, Burns W H, Lietman P S, et al. Prophylaxis: a strategy to minimize antiviral resistance. Lancet 1984; 1: 1154–1155
   PubMed Web of Science ®Google Scholar
• Saral R, Ambinder R F, Burns W H, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. Ann Intern Med 1983; 99: 773–776
   PubMed Web of Science ®Google Scholar
• Wade J C, Newton B, Flournory N, et al. Acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984; 100: 823–828
   PubMed Web of Science ®Google Scholar
• Shepp D H, Dandliker P S, Flourmoy N, et al. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients. Transplantation 1987; 43: 654–658
   PubMed Web of Science ®Google Scholar
• Atkinson K, Meyers J D, Storb R, et al. Varicella zoster infections after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980; 29: 47–50
   PubMed Web of Science ®Google Scholar
• Luby J P, Ramirez-Ronda C, Rinner S, et al. A longitudinal study of varicella-zoster virus infections in renal transplant recipients. J Infect Dis 1977; 135: 659–663
   PubMed Web of Science ®Google Scholar
• Spencer E S, Anderson H K. Clinically evident, non-terminal infections with herpes viruses and the wart virus in immunocompromised renal allograft recipients. Br Med J 1970; 1: 251–254
   PubMedGoogle Scholar
• Rand K H, Rasmussen L E, Pollard R B, et al. Cellular immunity and herpes virus infections in cardiac-transplant patients. N Engl J Med 1976; 296: 1372–1377
   Web of Science ®Google Scholar
• Locksley R M, Flournoy N, Sullivan K M, Meyers J D. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152: 1172–1181
   PubMed Web of Science ®Google Scholar
• Ljungman P, Lonnqvist B, Gahrton G, et al. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 1986; 153: 840–848
   PubMed Web of Science ®Google Scholar
• Ballow M, Hirshhorn R. Varicella pneumonia in a bone marrow-transplanted immune-reconstituted adenosine deaminase-deficient patient with severe combined immunodeficiency disease. J Clin Immunol 1985; 5: 180–186
   PubMed Web of Science ®Google Scholar
• Bertotto A, Gentili F, Vaccaro R. Immunoregulatory T cells in varicella. N Engl J Med 1982; 307: 1271–1272
   PubMed Web of Science ®Google Scholar
• Kumagai T, Chiba Y, Wataya Y, et al. Development and characteristics of the cellular immune response to infection with varicella-zoster virus. J Infect Dis 1980; 141: 7–13
   PubMedGoogle Scholar
• Schucter L, Wingard J, Piantadosi S, et al. Herpes zoster infection following autologous bone marrow transplantation (ABMT). Blood 1988; 72: 406a
   Google Scholar
• Vilde J L, Bricaire F, Leport C, et al. Comparative trial of acyclovir and vidarabine in disseminated varicella-zoster virus infections in immunocompromised patients. J Med Virol 1986; 20: 127–134
   PubMed Web of Science ®Google Scholar
• Shepp D H, Dandliker P S, Meyers J D. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med 1986; 314: 208–212
   PubMed Web of Science ®Google Scholar
• Levin M J, Zaia J A, Hershey B J, et al. Topical acyclovir treatment of herpes zoster in immunocompromised patients. J Am Acad Dermatol 1985; 13: 590–596
   PubMed Web of Science ®Google Scholar
• Groth K E, McCullough J, Marker S C, et al. Evaluation of zoster immune plasma. JAMA 1978; 239: 1877–1879
   PubMed Web of Science ®Google Scholar
• Stevens D A, Merigan T C. Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts: a randomized trial. Arch Int Med 1980; 140: 52–54
   PubMed Web of Science ®Google Scholar
• Saral R, Burns W H, Prentice H G. Herpes virus infections: clinical manifestations and therapeutic strategies in immunocompromised patients. Clin Haematol 1984; 13: 645–660
   PubMedGoogle Scholar
• Hanto D W, Frizzera G, Gajl-Peczalska J, et al. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461
   PubMed Web of Science ®Google Scholar
• Fizzera G, Hanto D W, Gajl-Peczalska K J, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262
   PubMed Web of Science ®Google Scholar
• Zutter M M, Martin P J, Sale G E, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520–529
   PubMed Web of Science ®Google Scholar
• Gratama J W, Oosterveer M AP, Zwaan F E, et al. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci (USA) 1988; 85: 8693–8696
   PubMed Web of Science ®Google Scholar
• Townsend T R, Bolyard E A, Yolken R H, et al. Outbreak of cox-sackie A1 gastroenteritis: a complication of bone-marrow transplantation. Lancet 1982; 1: 820–823
   PubMed Web of Science ®Google Scholar
• Yolken R H, Bishop C A, Townsend T R, et al. Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med 1982; 306: 1009–1112
   Web of Science ®Google Scholar
• Lownosky G A, Johnson J P, Winkelstein J A, Yolken R H. Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. J Clin Invest 1985; 76: 2362–2367
   PubMed Web of Science ®Google Scholar
• Shields A F, Hackman R C, Fife K H, et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 1985; 312: 529–533
   PubMed Web of Science ®Google Scholar
• Arthur R R, Shah K V, Baust S J, Santos G W, Saral R. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med 1986; 315: 230–234
   PubMed Web of Science ®Google Scholar
• Aruthur R R, Shah K V, Charache P, Saral R. BK and JC virus infections in recipients of bone marrow transplants. J Infect Dis 1988; 158: 563–569
   PubMed Web of Science ®Google Scholar
• Ambinder R F, Burns W, Forman M, et al. Hemorrhagic cystitis associated with adenovirus infection in bone marrow transplantation. Arch Int Med 1986; 146: 1400–1401
   PubMed Web of Science ®Google Scholar